Big news from @FoundationATCG:
They now offer a tissue-informed WGS MRD test (RUO) that can detect ctDNA at super low levels (0.001%).
Available via their FlexOMx Lab™ for cancer research across early → late stages.
This could help researchers better track treatment response & predict recurrence.
Read more about this here: https://foundationmedicine.com/press-release/mrd-test-ruo